2022 | Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study | Simonelli, M; Garralda, E; Eskens, F; Gil-Martin, M; Yen, C-J; Obermannova, R; Chao, Y; Lonardi, S; Melichar, B; Moreno, V; Yu, M-L; Bongiovanni, A; Calvo, E; Rottey, S; Machiels, J-P; Gonzalez-Martin, A; Paz-Ares, L; Chang, C-L; Mason, W; CHIA-CHI LIN ; Reardon, D A; Vieito, M; Santoro, A; Meng, R; Abbadessa, G; Menas, F; Lee, H; Liu, Q; Combeau, C; Ternes, N; Ziti-Ljajic, S; Massard, C | ESMO open | 12 | 8 | |